|
News For ARNA;VVUS;OREX From The Last 14 Days Check below for free stories on ARNA;VVUS;OREX the last two weeks. |
|
|
| May 17, 2013 |
| 11:53 EDT |  | ARNA | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 15, 2013 |
| 14:03 EDT |  | ARNA | Arena Pharma has positive read through from Eisai forecast, says Piper Jaffray
Subscribe for More Information |
|
| 06:19 EDT | | ARNA | Arena Pharmaceuticals implied volatility at lower end of index mean range
Subscribe for More Information |
|
| May 14, 2013 |
| 10:01 EDT |  | VVUS | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 07:33 EDT | | VVUS | VIVUS downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information |
|
| May 13, 2013 |
| 07:41 EDT |  | VVUS | VIVUS mails letter to stockholders providing business update
Subscribe for More Information |
|
| May 8, 2013 |
| 16:11 EDT |  | OREX | Orexigen reports Q1 EPS (21c), consensus (34c)
Reports Q1 revenue $857,000, consensus $890,000. |
|
| 07:35 EDT | | VVUS | VIVUS reports Q1 EPS (53c), consensus (51c)
Reports Q1 revenue $4.11M, consensus $5.22M. |
|
| 05:52 EDT | | ARNA | Stocks with implied volatility movement; ARNA ANR
Stocks with implied volatility movement; Arena Pharmaceuticals (ARNA), Alpha Natural (ANR) according to IVolatility. |
|
| May 7, 2013 |
| 16:54 EDT |  | ARNA | On The Fly: Closing Wrap
Subscribe for More Information |
| |
| 16:52 EDT | | VVUS | First Manhattan Co. releases case for full board change at VIVUS
Subscribe for More Information |
|
| 15:33 EDT | | ARNA | Arena to receive $65M in milestone payments from Eisai related to Belviq
Subscribe for More Information |
|
| 14:16 EDT | | ARNA | Arena climbs after DEA takes action on anti-obesity drug
Arena Pharmaceuticals (ARNA) is rallying after the Drug Enforcement Administration determined that the company's anti-obesity drug, lorcaserin, has relatively low potential for abuse. In a note to investors, research firm Piper Jaffray wrote that the DEA's action indicates that lorcaserin will be launched in the U.S. on or around June 7. WHAT'S NEW: The DEA announced in a written statement that it was declaring lorcaserin to be a Schedule IV drug. Schedule IV drugs are defined as drugs with a low potential for abuse and low risk of dependence, according to the Justice Department. In a note to investors, Piper Jaffray analyst Edward Tenthoff predicted that Arena's partner, Eisai, would launch lorcaserin in the U.S. on or around June 7. In addition, the DEA's action will trigger payments of $65M to Arena from Eisai this quarter, according to the analyst. Lorcaserin should generate revenue of $22M this year and $141M next year for Arena, added the analyst, who kept an Overweight rating on the stock. TODAY'S PRICE ACTION: In mid-afternoon trading, Arena gained 85c, or 11.30%, to $8.37. |
|
| 12:58 EDT | | ARNA | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 10:43 EDT | | ARNA | DEA places Arena weight loss drug into Schedule IV
The Drug Enforcement Administration issued a final ruling that places the substance lorcaserin into Schedule IV of the Controlled Substances Act. Lorcaserin, a weight-loss drug developed by Arena Pharmaceuticals, is also known by the trade name Belviq. In issuing the ruling, the DEA denied a request to waive a 30-day waiting period for launch following the scheduling. Reference Link |
|
| May 6, 2013 |
| 10:00 EDT |  | OREX | Orexigen management to meet with JPMorgan
Subscribe for More Information |
|
|
|
|
|
